Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
about
OATPs, OATs and OCTs: the organic anion and cation transporters of the SLCO and SLC22A gene superfamiliesMembrane transporters in drug developmentPrediction of hepatic clearance in human from in vitro data for successful drug development.Xenobiotic, bile acid, and cholesterol transporters: function and regulation.The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.Pitavastatin approved for treatment of primary hypercholesterolemia and combined dyslipidemia.Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice.Pharmacokinetic interaction between nelfinavir and pravastatin in HIV-seronegative volunteers: ACTG Study A5108.Pitavastatin: a new HMG-CoA reductase inhibitor.The role of OATP1B1 and BCRP in pharmacokinetics and DDI of novel statins.Pleiotropic effects of pitavastatinPharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney.Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin responseContribution of hepatic organic anion-transporting polypeptides to docetaxel uptake and clearanceIsolation of modulators of the liver-specific organic anion-transporting polypeptides (OATPs) 1B1 and 1B3 from Rollinia emarginata Schlecht (Annonaceae).Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.Pharmacokinetic Properties of Single- and Multiple-Dose Pitavastatin Calcium Tablets in Healthy Chinese Volunteers.SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patientsFrequencies of single-nucleotide polymorphisms and haplotypes of the SLCO1B1 gene in selected populations of the western balkans.Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans.Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146.HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphismsRole of OATP transporters in the disposition of drugs.Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signaling and ADME.PhRMA white paper on ADME pharmacogenomics.Effects of drug transporters on volume of distribution.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.OATP1B1-related drug-drug and drug-gene interactions as potential risk factors for cerivastatin-induced rhabdomyolysis.Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care.Transporter pharmacogenetics and statin toxicity.Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testingHepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Efflux and uptake transporters as determinants of statin response.Lack of effect of genetic polymorphisms of SLCO1B1 on the lipid-lowering response to pitavastatin in Chinese patients.Are all statins the same? Focus on the efficacy and tolerability of pitavastatin.Statin dose in Asians: is pharmacogenetics relevant?The evolution of the OATP hepatic uptake transport protein family in DMPK sciences: from obscure liver transporters to key determinants of hepatobiliary clearance.Current understanding of hepatic and intestinal OATP-mediated drug-drug interactions.Pitavastatin: a review of its use in the management of hypercholesterolaemia or mixed dyslipidaemia.
P2860
Q27001267-63775C1B-CFCE-4FDB-B411-C66294164C0DQ29616802-D45EB80E-0B71-4BEC-92C8-62D5934889C6Q33437736-8A1972B5-927C-4E90-B27D-681CC8EB0346Q33714593-C59D5355-2354-4E24-A85C-B9E12CEC78C3Q34216710-54C87974-D022-4977-A3F6-9D8D15AE8244Q34276618-701CF7EE-9691-4914-9C64-BAA6F4038292Q34334852-66DD7C3C-1EBB-48CB-86B5-53D500B5C674Q34579707-6667EC64-6915-423F-891A-BB130EF7AAB9Q34599850-24FE7709-E945-4735-87A3-BD8B5AF93766Q34617057-657AD105-2A7D-42D2-BB4E-95DE014554A0Q34631971-1A782B69-D9EB-41CD-B11F-9680E9BAF389Q34633506-53E1A2E9-E88E-47C0-88D8-9BBA722AE62FQ34777362-7ABE49F7-348E-4304-8035-0D3328413DD1Q35297067-1A82AB7F-4EFE-47E1-9E71-7DB7994DBD92Q35375045-612A5691-F5A1-4560-B7D0-8A3CC57C978AQ35430039-A7AF4F6A-1CB0-4098-811A-A5D17CD0919DQ35607718-BD6710BE-4072-4C9D-94AE-AE5E3C6201BDQ35697517-D276419F-9212-4F4B-A004-C314109FEB99Q36024636-777F2D92-839D-4AFD-9C4B-9753CF55D0E9Q36623470-DC90B943-8213-466A-8023-57EBAE1B8922Q36687277-E0D695B2-CBCD-4851-BF9A-A3BF87C9B0ADQ36701911-C049AE9F-CBA8-4BD8-8B4B-1C9E0410F030Q36877910-3F1E20A2-A4C7-468C-B694-D6D3B31CEE47Q37074085-85BD2B9B-7803-40CE-918B-0D586ED152BEQ37121662-A1900D5C-3D26-410F-9F39-5CA6B87BE448Q37182212-F546352F-ACF6-4E1C-BDBF-99765E341301Q37214523-20EC1507-1EA8-48EE-BC1A-DC581A2A940AQ37481450-BDA412CA-37E8-497D-B8C9-C6C6E83EC627Q37489569-C93AA9BB-4A4D-481F-9BC3-B3CC2DD7E2D6Q37579733-DC96E23C-4A50-40C0-94D9-8A6C27F992DCQ37627544-B7B2A729-45D8-4F3E-8891-4E46325E1EF3Q37652863-65D8E11F-C3AB-45E8-9810-49B91C18D0D4Q37680968-4E95023E-25A0-464E-AD85-7345BAA63EA9Q37724381-379976A3-EA86-4227-AD5A-9602EABCFAC4Q37728163-30445DF4-3209-48A8-8029-BC649043FF6FQ37859000-0370821D-8631-4F09-8553-4809A4C91963Q37951651-E627020D-9778-4556-A771-F42616E74EC0Q37955160-6A41CD64-5009-4B4B-812A-8BA406AEF057Q37960129-2A85585B-B7B8-4015-AE13-CE193E69C6C9Q37987212-6D26D60F-3745-4550-BB8D-24AB5D20D308
P2860
Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Effect of OATP1B1 (SLCO1B1) va ...... astatin in healthy volunteers.
@en
type
label
Effect of OATP1B1 (SLCO1B1) va ...... astatin in healthy volunteers.
@en
prefLabel
Effect of OATP1B1 (SLCO1B1) va ...... astatin in healthy volunteers.
@en
P2093
P1476
Effect of OATP1B1 (SLCO1B1) va ...... vastatin in healthy volunteers
@en
P2093
Hye-Ryung Jung
In-Jin Jang
Jae-Yong Chung
Joo-Youn Cho
Jung-Ryul Kim
Ki-Ho Moon
Kyoung-Soo Lim
Kyung-Sang Yu
Sang-Goo Shin
P304
P356
10.1016/J.CLPT.2005.07.003
P407
P50
P577
2005-10-01T00:00:00Z